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Abstract
A rapid method to determine the systemic incorporation of amifostine has been sought in order to determine the effectiveness of different
administration routes without the delay inherent in awaiting therapeutic results. Consistent changes in animal measurements of nitroxide
signal decay were monitored using in vivo EPR at frequencies low enough to ensure uniform sensitivity to organs deep in 20-g C3H mice.
Conditions included both co-administration of the amifostine with the carbamoyl-proxyl spin probe (CP) via i.p. injection (n = 6) and oral
administration (n = 8) of the amifostine. These decreased the first order rate of decay of the CP EPR signal after a dose of 13.5 Gy radiation,
by 23% and 18%, respectively. These changes were significantly different from the rate of decay of the CP EPR signal without amifostine,
but were statistically indistinguishable from each other. These data demonstrate: (1) condition-dependent exponential decay of CP EPR signal
allowing its use to determine systemic availability of a drug, and (2) that oral administration and i.p. injection of amifostine are both effective
in affecting the CP EPR signal decay rate in a mouse model. This is a strong indicator of similar bioavailability in mice from both routes of
administration.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Introduction
Amifostine (WR-2721) is a classical radiation protector
originally investigated for potential clinical use (e.g. Yuhas
[1–4]). The drug’s use derived from its ability to selectively
protect normal but not malignant tissues from radiation and
chemotherapy. This has been demonstrated in animal mod-
els and to a more limited extent for patients being treated for
cancer and/or for people acutely exposed to ionizing radi-
ation [5–7]. A significant limitation in the use of amifostine
has been the need to administer it intravenously to ensure
maximum bioavailability. It would be more convenient if an
oral form of the compound could be used. The comparison
of various forms of administration ultimately will need to
await the results from therapeutic administration for vali-
dation. However, rapid screening of a large group of
protective agents would be enhanced by rapid measure-
ments of bioavailability. Serum measurements require at
least several time points and chemical analysis that is
specific for the compound. These can be both difficult and
expensive for the routine screening of new generations of
amifostine-like drugs. In addition, these assays do not allow
for the determination of biologically relevant activity.
Whole-body nitroxide reduction has been used previ-
ously to test a large group of radioprotectors [8]. This
approach was initiated with the assumption that cellular
and tissue reduction of nitroxides is sensitive to the overall
reductive capacity of the system that was altered by the
protector. This assumption is not, however, necessary for the
use of the assay to reflect availability in vivo, following the
administration of the drug. Irradiation at a dose of 15 Gy has
been reported to significantly increase the decay rate of
nitroxide [9]. The mechanism of this effect is complex, but
the data [8] indicate that the effect can be reversed by the
use of classical free radical scavenging agents. Therefore,
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the process of nitroxide EPR signal decay reflects an in vivo
interaction between radiation and the drug being evaluated.
In order for this interaction to take place, it requires that the
drug be bioavailable.
The goal of this study was to confirm the effect of
amifostine on nitroxide reduction rate in a mouse after
radiation and to determine whether oral administration of
WR-2721 is as effective in making the drug available as
giving the drug via intraperitoneal injection.
2. Materials and methods
2.1. Chemicals
Amifostine, an organic thiophosphate cytoprotective
agent (ethanethiol, 2-[(3-aminopropyl)amino]-, dihydrogen
phosphate ester) was obtained from The Drug Synthesis and
Chemistry Branch, Division of Cancer Treatment, National
Cancer Institute, Bethesda, MD, USA. The dose of 400 mg/
kg was given to animals either i.p. (30 min before irradi-
ation) or orally by gavage (2 h before irradiation), in a water
solution. Nitroxide spin probe, carbamyol-proxyl, CP (3-
carbamoyl-2,2,5,5-tetramethyl-pyrrolidine-N-oxyl), was
synthesized and given generously by Dr. Gerald Rosen
from University of Maryland, Baltimore.
2.2. Animals
C3H/HeN, 4–6 weeks old, female mice were purchased
from Harlan Sprague Dawley (Indianapolis, IN). Animals
were maintained on a standard diet. The experimental
protocol was approved by the University of Chicago Animal
Care and Use Committee and was consistent with federal,
state and local regulations. Mice were euthanized with a
lethal dose of Pentobarbital (240 mg/kg) after the comple-
tion of the experiment.
2.3. EPR spectroscopy
Animals were anesthetized i.p. with 20 mg/kg of diaze-
pam plus 45 mg/kg of Ketamine. A 30-gauge needle was fit
snugly into 0.28 mm ID (PE-10, Clay Adams Brand, Becton
Dickinson, Sparks, MD, USA) polyethylene tubing and
connected to a 1-ml syringe containing CP. The other end
of the polyethylene tubing was inserted into the peritoneal
cavity. The tubing was secured to the skin using SuperGlue.
The mouse was placed in a Plexiglas restrainer by taping the
limbs to the ends of the restrainer. A rectal temperature
probe was installed. The mouse was then positioned in the
cavity of the low frequency EPR spectrometer. The animal
was placed in the resonator such that the resonator active
volume covered the section of the body from the just above
the diaphragmatic domes to just above the pelvis. This
effectively excluded the bladder and included the domes
of the diaphragms, as was verified by both autopsy and by
X-ray with i.v. contrast to visualize the bladder. The mouse
was kept at 33–36 jC with heating lamps placed on both
sides of the resonator.
Spectra were taken immediately after the injection of
100 Al of 280 mM solution of CP through the i.p. line.
Typically, three scans of 256 points were collected every
minute for approximately 20–30 min. RF power at the
resonator was 10 mW, modulation amplitude 1 G peak-to-
peak.
2.4. Irradiation
X-ray irradiation was performed using Pantak PMC 1000
X-ray generator (150 kV, 25 mA, dose rate of 1.92 Gy/min).
A single dose of 13.5 Gy on average was administered to
the whole body of a mouse, immobilized without anesthesia
in a Plexiglas tube.
2.5. Animal treatment groups
Animals were divided into four experimental groups.
Control EPR signal decay was measured in untreated
animals (group 1). Group 2 was irradiated 1 h before
measurement of nitroxide EPR signal decay. A dose of
400 mg/kg of amifostine was given either i.p. (group 3) or
orally (group 4). Radioprotection has been demonstrated
with this dose in earlier mouse studies [6]. Amifostine was
administered to animals from group 3 i.p. half an hour prior
to irradiation and 1 1/2 h prior to measurement of CP EPR
signal decay. Group 4 received 150–200 Al of amifostine
orally 2 h before irradiation and 3 h preceding CP EPR
signal decay measurement. This gave a consistent 1-h delay
between radiation and EPR signal decay measurement. The
additional 1 1/2 h between oral administration and radiation
relative to i.p. administration compensated for the slower
absorption of the oral amifostine administration as has been
previously demonstrated [10].
2.6. Data analysis
The half-life of CP was calculated by applying a linear
regression model to the natural logarithm of the fitted
spectral intensity over time. Spectral intensity was deter-
mined using the algorithms of Robinson et al. [11].
The test chosen for analysis of significance was the
Kruskal–Wallis nonparametric rank test. It does not require
that the sample groups derive from normally distributed
populations with equal variances. It is a nonparametric
analysis of variance for use with three or more groups with
different individuals receiving different treatments. The
actual analysis was done with PRIMER [12] software.
The Kruskal–Wallis test was performed on groups 1, 3
and 4. The value of H was calculated from these groups. In
this case H can be compared to v2 test with 2 degrees of
freedom (3 groups—1) and a P value was obtained from the
v2. For multiple comparisons against the control (Group 1 in
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this case) with groups having unequal sample sizes, Dunn’s
nonparametric test was used.
3. Results
After i.p. injection of CP a typical pharmacokinetic
response can be observed: i.e., a short (1–3 min) phase of
distribution during which the signal increases, followed by
signal decay. Whole-body irradiation alone did not decrease
the EPR signal half-life significantly. Treatment with ami-
fostine given i.p. prior to radiation slowed the process of
decay by 23%. Oral administration of amifostine also
decreased the EPR signal decay, by 18% (Fig. 1, Table 1).
The Kruskal–Wallis test was performed on groups 1, 3 and
4 and the value of H was found to be 11.772. This value of
H when compared to v2 test with 2 degrees of freedom (3
groups—1) gives a P value of 0.003. This means that
amifostine had an effect in at least one of the experimental
groups. The application of Dunn’s nonparametric test to
comparisons against the control (Group 1 in this case) with
groups having unequal sample sizes gave QV values, Group
3 vs. Group 1 and Group 4 vs. Group 1, which were greater
than the critical values with k = 3 (see Table 2), with
P < 0.05 in both cases. Therefore, it can be concluded that
amifostine had an effect in both experimental groups.
The similarity of the effects of the oral and the i.p. routes
indicates that oral administration of amifostine provides a
bioavailable compound in the mouse with nearly the same
efficacy. The number of animals used here would show a
difference between groups equal to the standard deviation of
the measurements in the group populations with a power of
0.55. Here the difference between the oral and i.p. delivery
was a bioreduction rate difference of approximately 30% the
standard deviation of the populations (Table 2), a value too
small to infer a difference.
4. Discussion
Amifostine is a highly efficient radioprotector, demon-
strated to protect mice, dogs and rhesus monkeys against X-
ray radiation and mice against neutron radiation [10] in
survival studies, when administered i.p. or i.v. Oral admin-
istration studies, however, were not conclusive. The results
of a single survival study using an oral dose of 700 mg/kg
(1/2 LD50) showed protection in mice, whereas in rhesus
monkeys, with a dose of 300 mg/kg, no protection was
observed [10]. These results led to the conclusion that
amifostine was not orally bioavailable in larger animals
and that for clinical applications it should be administered
i.v.
One of the reasons for the reported failure of amifostine
to exert protection in rhesus monkeys might be that the dose
used in these experiments was low and that time between
oral administration and radiation was too short (30 min), not
allowing for adequate distribution of the drug. The survival
studies in larger animals were never repeated because of the
time and high costs involved.
Other studies, using the area of the uptake curve of
amifostine in blood as an endpoint, are not sufficient to
Table 1
The in vivo half-life of CP (min)
X-ray+CP
(Group 2)
CP only
(Group 1)
Amifostine
IP+X-ray+CP
(Group 3)
Oral Amifostine
+X-ray+CP
(Group 4)
14.51 15.82 22.89 19.2
15.21 15.99 14.52 18.05
11.55 13.86 16.95 18.01
14.64 21.53 18.34
14.29 18.05 17.55
16.95 18.62 21.19
15.2 17.33
12.8 14.14
16.56
16.05
16.57
13.86
13.96 15.21 18.76 17.97 Mean
1.64 1.31 3.05 1.97 Standard
Deviation
1.16 0.40 1.36 0.75 Standard
Error
Fig. 1. Comparison of CP signal decay in vivo in mice treated with CP only,
radiation, amifostine given IP and orally. Bars represent means with
standard error (standard deviation in for X-ray group).
Table 2
Analysis of significance using Kruskal–Wallis test and Dunn’s non-
parametric test for comparisons against the control
H
(P=0.003)
v2
(P=0.003)
df=2
QV
Calculated
(P<0.05)
QV
critical
(P=0.01)
k=3
Significance
All groups 11.72 11.62 Yes
Group 3 vs. 1 2.845 2.807 Yes
Group 4 vs. 1 2.824 2.807 Yes
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provide adequate information on its bioavailability. Amifos-
tine is rapidly converted to its free thiol form in the blood
stream within minutes after administration [7,13]. The free
thiol is rapidly oxidized into its disulfide form, a molecule
that closely resembles the polyamine spermine in both
structure and function, which can then be taken up by cells
via their polyamine transporter system [14]. Both the thiol
and disulfide metabolites of amifostine are then actively
concentrated in the mitochondria and nucleus of cells. The
rapid disappearance of these metabolites from the blood is
not indicative of their radical scavenging ability. Rather,
their rapid incorporation into cells is the basis for their
cytoprotective effectiveness.
Our results, demonstrating that oral administration of
amifostine is as effective as the same dose given i.p. in mice,
are consistent with early survival studies [10] and previous
EPR studies. Miura et al. have used whole-body EPR signal
decay to evaluate anti-oxidant properties of a group of
radioprotectors. They compared EPR signal decay rate of
a nitroxide in animals treated with radiation in the presence
and absence of radioprotectors [8]. The nitroxide signal
decay half-life after WR-2721 was decreased by 12%,
similar to our experiments.
Nitroxides in vivo can undergo several redox reactions,
which yield EPR-silent products [15–19]. While it is
difficult to describe fully the mechanism for the decay of
the EPR signal, others have used cellular or tissue nitroxide
‘‘EPR signal decay’’, including all redox processes leading
to nitroxide EPR signal decay, as a measure of oxidative
stress in various models [15,20,21]. This assumes that there
is no change in perfusion, uptake, excretion or other
reactions; there is little evidence to support the validity of
all of these assumptions.
In our experiments the nitroxide signal was collected from
the upper part of the mouse body. Paramagnetic spin probe
that accumulated in the bladder was excluded from the
measurement. Whether or not this affects the interpretation
of the mechanism of the decay rate, this does not interfere
with the object of this paper: to develop a method to assess
the dependence on administration route of a biological effect
of amifostine. This in turn will give a prompt measure of the
bioavailability of amifostine. By bioavailability, we mean
simply that the compound has penetrated into some fluid
compartment of a viable living system. There it can modify
products of interaction with radiation which affect the decay
of the carboxy-proxyl EPR signal.
Oral administration is a convenient, although not always
equally effective, drug administration route. Kinetics of
drug uptake and distribution might be dramatically different
from those after intraperitoneal administration. Our results
show that, taking into account the additional time required
for uptake and distribution of amifostine, there is no
significant difference in the ability to affect the nitroxide
signal between oral and i.p. administration of this drug.
This approach could be used in larger animals to evaluate
drug bioavailability using a low frequency EPR system with
resonators that are capable of measurements in dogs and
rhesus monkeys.
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